Evaluation of the duration of thromboembolic prophylaxis after high-risk orthopaedic surgery: The ETHOS observational study

Summary

Real-life data on post-discharge venous thromboembolism (VTE) prophylaxis practices and treatments are lacking. We assessed post-operative VTE prophylaxis prescribed and received in a prospective registry, compared with the 2004 American College of Chest Physicians (ACCP) guidelines in high-risk orthopaedic surgery patients. Consecutive patients undergoing total hip arthroplasty (THA), hip fracture surgery (HFS), or knee arthroplasty (KA) were enrolled at discharge from 161 centres in 17 European countries if they had received in-hospital VTE prophylaxis that was considered in accordance with the ACCP guidelines by the treating physician. Data on prescribed and actual prophylaxis were obtained from hospital charts and patient post-discharge diaries. Post-operative prophylaxis prescribed and actual prophylaxis received were considered adherent or adequate, respectively, if recommended therapies were used for ≥28 days (HFS and THA) or ≥10 days (KA). Among 4,388 patients, 69.9% were prescribed ACCP-adherent VTE prophylaxis (THA: 1,411/2,217 [63.6%]; HFS: 701/1,112 [63.0%]; KA: 955/1,059 [90.2%]). Actual prophylaxis received was described in 3,939 patients with an available diary after discharge (non-evaluability rate of 10%). Mean actual durations of pharmacological prophylaxis from surgery were: 28.4 ± 13.7 (THA), 29.3 ± 13.9 (HFS), and 28.7 ± 14.1 days (KA). ACCP-adequate VTE prophylaxis was received by 66.5% of patients (60.9% THA, 55.4% HFS, and 88.7% KA). Prophylaxis inadequacies were mainly due to inadequate prescription, non-recommended prophylaxis prescription at discharge, or too short prophylaxis prescribed. In high-risk orthopaedic surgery patients with hospital-initiated prophylaxis, there is a gap between ACCP recommendations, prescribed and actual prophylaxis received, mainly due to inadequate prescription at discharge.

Keywords

Hip fracture surgery - knee arthroplasty - prophylaxis - total hip arthroplasty - venous thromboembolism

^* Listed in Appendix.

• References

• 1 Geerts WH, Bergqvist D, Pineo GF. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl. 06) 381S-453S.
• 2 Guijarro R, Montes J, San Roman C. et al. Venous thromboembolism and bleeding after total knee and hip arthroplasty. Findings from the Spanish National Discharge Database. Thromb Haemost 2011; 105: 610-615.
• 3 Collins R, Scrimgeour A, Yusuf S. et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318: 1162-1173.
• 4 Agnelli G.. Prevention of venous thromboembolism in surgical patients. Circulation 2004; 110 (Suppl. 01) IV4-IV12.
• 5 Bergqvist D, Lindblad B.. A 30-year survey of pulmonary embolism verified at autopsy: an analysis of 1274 surgical patients. Br J Surg 1985; 72: 105-108.
• 6 Bergqvist D, Agnelli G, Cohen AT. et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.. N Engl J Med 2002; 346: 975-980.
• 7 Bergqvist D.. The postdischarge risk of venous thromboembolism after hip replacement. The role of prolonged prophylaxis. Drugs 1996; 52 (Suppl. 07) 55-59.
• 8 Warwick D, Friedman RJ, Agnelli G. et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry.. J Bone Joint Surg Br 2007; 89: 799-807.
• 9 Bergqvist D, Benoni G, Bjorgell O. et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700.
• 10 Planes A, Vochelle N, Darmon JY. et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-228.
• 11 Hull RD, Pineo GF, Stein PD. et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review.. Ann Intern Med 2001; 135: 858-869.
• 12 Friedman RJ.. Extended thromboprophylaxis after hip or knee replacement. Orthopedics 2003; 26 (Suppl. 02) S225-S230.
• 13 Eikelboom JW, Mazzarol A, Quinlan DJ. et al. Thromboprophylaxis practice patterns in two Western Australian teaching hospitals.. Haematologica 2004; 89: 586-593.
• 14 Geerts WH, Pineo GF, Heit JA. et al. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 338S-400S.
• 15 Cardiovascular Disease Educational and Research Trust. Cyprus Cardiovascular Disease Educational and Research Trust; European Venous Forum; et al. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006; 25: 101-161.
• 16 Arnold DM, Kahn SR, Shrier I.. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest 2001; 120: 1964-1971.
• 17 Vallano A, Arnau JM, Miralda GP. et al. Use of venous thromboprophylaxis and adherence to guideline recommendations: a cross-sectional study. Thromb J 2004; 2: 3.
• 18 Tapson VF, Hyers TM, Waldo AL. et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines.. Arch Intern Med 2005; 165: 1458-1464.
• 19 Cohen AT, Tapson VF, Bergmann JF. et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study.. Lancet 2008; 371: 387-394.
• 20 Friedman RJ, Gallus AS, Cushner FD. et al. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty.. Curr Med Res Opin 2008; 24: 87-97.
• 21 Karve S, Cleves MA, Helm M. et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data.. Curr Med Res Opin 2009; 25: 2303-2310.
• 22 Bikdeli B, Sharif-Kashani B, Raeissi S. et al. Chest physicians' knowledge of appropriate thromboprophylaxis: insights from the PROMOTE study. Blood Coagul Fibrinolysis. 2011 in press.
• 23 Weigelt JA, Lal A, Riska R.. Venous thromboembolism prophylaxis in surgical patients: identifying a patient group to maximize performance improvement. Jt Comm J Qual Patient Saf 2011; 37: 178-83.
• 24 Schleyer AM, Schreuder AB, Jarman KM. et al. Adherence to guideline-directed venous thromboembolism prophylaxis among medical and surgical inpatients at 33 academic medical centers in the United States.. Am J Med Qual 2011; 26: 174-180.
• 25 Amin AN, Stemkowski S, Lin J. et al. Preventing venous thromboembolism in US hospitals: are surgical patients receiving appropriate prophylaxis?. Thromb Haemost 2008; 99: 796-797.
• 26 Borah B, McDonald H, Henk J. et al. Alignment to ACCP prophylaxis guidelines and VTE outcomes in THR and TKR patients [abstract]. Blood. 2008 112. Abstract 170.
• 27 American Academy of Orthopaedic Surgeons clinical guideline on prevention of pulmonary embolism in patients undergoing total hip or knee arthroplasty, May 2007. http://www.aaos.org/Research/guidelines/PE_guideline.pdf Accessed February 21, 2011.
• 28 Eikelboom J, Karthikeyan G, Fagel N. et al. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients?. Chest 2009; 135: 513-520.
• 29 Rahme E, Dasgupta K, Burman M. et al. Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery.. CMAJ 2008; 178: 1545-1554.
• 30 Labarère J, Bosson JL, Bergmann JF. et al. Agreement of four competing guidelines on prevention of venous thromboembolism and comparison with observed physician practices: a cross-sectional study of 1,032 medical inpatients.. J Gen Intern Med 2004; 19: 849-855.
• 31 Spyropoulos AC.. Outpatient-based primary and secondary thromboprophylaxis with low-molecular-weight heparin. Clin Appl Thromb Hemost 2008; 14: 63-74.
• 32 Beeler PE, Kucher N, Blaser J.. Sustained impact of electronic alerts on rate of prophylaxis against venous thromboembolism. Thromb Haemost. 2011; 106: 734-738.
• 33 Fiumara K, Piovella C, Hurwitz S. et al. Multi-screen electronic alerts to augment venous thromboembolism prophylaxis.. Thromb Haemost. 2010; 103: 312-317.
• 34 Tooher R, Middleton P, Pham C. et al. A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals.. Ann Surg 2005; 241: 397-415.